RPMI 8226/GFP-Firefly Luciferase Cell Line

Description: RPMI 8226 is a human multiple myeloma cell line originally derived from a patient with plasmacytoma. These cells constitutively express BCMA and CD38, making them a physiologically relevant model for evaluating cancer immunotherapies, including Chimeric Antigen Receptor (CAR) T cells. The RPMI 8226/GFP-firefly luciferase variant stably expresses both GFP and firefly luciferase, enabling use in in vitro cytotoxicity assays and in vivo studies.

Quantity: Two vials of frozen cells (2×106 per vial)

Stability: Stable in culture over a minimum of 10 passages

Application: Drug screening, biological assays and in vivo study

Freezing Medium: 7% RPMI 1640 +20% FBS+10% DMSO

Propagation Medium: RPMI1640+10%FBS

Morphology: Lymphoblast

Subculture: Start cultures 5.0 X 105 cells/mL maintain between 1.0 X 105 and 2.0 X 106 cells/mL.

Incubation: 37 °C with 5% CO2

Storage: Liquid nitrogen immediately upon receiving

Doubling Time: Approximately 26 hours

Mycoplasma Status: Negative

Caution: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information.